Kymera Therapeutics (KYMR) News Today $44.05 +1.21 (+2.82%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Stephens & Co. Initiates Coverage of Kymera Therapeutics (KYMR) with Overweight RecommendationNovember 20 at 11:24 AM | msn.comKymera Therapeutics (NASDAQ:KYMR) Now Covered by StephensStephens assumed coverage on shares of Kymera Therapeutics in a research report on Monday. They issued an "overweight" rating and a $65.00 target price for the company.November 18 at 9:05 AM | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Shares Down 6.7% - Here's What HappenedKymera Therapeutics (NASDAQ:KYMR) Trading Down 6.7% - Should You Sell?November 15, 2024 | marketbeat.comAnalysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $51.21November 12, 2024 | americanbankingnews.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) have been given a consensus rating of "Moderate Buy" by the fifteen research firms that are currently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, ten have aNovember 9, 2024 | marketbeat.comKymera Therapeutics price target raised to $49 from $45 at Morgan StanleyNovember 7, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)November 6, 2024 | markets.businessinsider.comKymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $49.00Morgan Stanley upped their price target on Kymera Therapeutics from $45.00 to $49.00 and gave the company an "equal weight" rating in a research note on Wednesday.November 6, 2024 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | msn.comKymera Therapeutics to Participate in Upcoming November Investor ConferencesNovember 5, 2024 | globenewswire.comUBS Group Has Lowered Expectations for Kymera Therapeutics (NASDAQ:KYMR) Stock PriceUBS Group lowered their target price on shares of Kymera Therapeutics from $80.00 to $74.00 and set a "buy" rating for the company in a report on Monday.November 4, 2024 | marketbeat.comFY2024 Earnings Estimate for KYMR Issued By Leerink PartnrsKymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Research analysts at Leerink Partnrs lifted their FY2024 earnings estimates for shares of Kymera Therapeutics in a research note issued to investors on Thursday, October 31st. Leerink Partnrs analyst F. Khurshid now expects that the companyNovember 4, 2024 | marketbeat.comKymera Therapeutics, Inc. (KYMR) Q3 2024 Earnings Call TranscriptNovember 3, 2024 | seekingalpha.comKymera Therapeutics: Promising Immunology Pipeline and Strategic Focus on KT-621 and KT-474 ProgramsNovember 3, 2024 | markets.businessinsider.comKymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...November 1, 2024 | uk.finance.yahoo.comKymera Therapeutics Reports Q3 2024 Earnings and Strategic ShiftNovember 1, 2024 | markets.businessinsider.comKymera Therapeutics (KYMR) Gets a Buy from Truist FinancialNovember 1, 2024 | markets.businessinsider.comKymera Therapeutics (NASDAQ:KYMR) Stock Price Expected to Rise, Guggenheim Analyst SaysGuggenheim boosted their target price on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the stock a "buy" rating in a research report on Friday.November 1, 2024 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPSKymera Therapeutics (NASDAQ:KYMR - Get Free Report) released its earnings results on Thursday. The company reported ($0.82) earnings per share for the quarter, topping analysts' consensus estimates of ($0.83) by $0.01. The business had revenue of $3.74 million for the quarter, compared to the consensus estimate of $10.34 million. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. The firm's revenue for the quarter was down 20.9% compared to the same quarter last year. During the same period last year, the business earned ($0.90) earnings per share.November 1, 2024 | marketbeat.comKymera Therapeutics' (KYMR) "Buy" Rating Reiterated at Truist FinancialTruist Financial restated a "buy" rating and set a $53.00 price target (down previously from $54.00) on shares of Kymera Therapeutics in a research note on Friday.November 1, 2024 | marketbeat.comKymera Therapeutics: Strategic Focus and Promising Trials Justify Buy RatingNovember 1, 2024 | markets.businessinsider.comKymera Therapeutics Inc (KYMR) Q3 2024: Everything You Need To Know Ahead Of EarningsOctober 31, 2024 | finance.yahoo.comKymera Therapeutics (NASDAQ:KYMR) Shares Gap Down - Time to Sell?Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Down - Time to Sell?October 31, 2024 | marketbeat.comInsights Ahead: Kymera Therapeutics's Quarterly EarningsOctober 31, 2024 | benzinga.comKymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business UpdateOctober 31, 2024 | globenewswire.comLeerink Partners Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)October 25, 2024 | markets.businessinsider.comKymera doses first patient in Phase 1 trial of KT-621October 25, 2024 | markets.businessinsider.comKymera Therapeutics (KYMR) Scheduled to Post Quarterly Earnings on ThursdayKymera Therapeutics (NASDAQ:KYMR) will be releasing earnings before the market opens on Thursday, October 31, Zacks reports.October 24, 2024 | marketbeat.comKymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory DiseasesOctober 24, 2024 | globenewswire.comKymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31October 23, 2024 | globenewswire.comKymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 SymposiumOctober 23, 2024 | globenewswire.comKymera Therapeutics (NASDAQ:KYMR) Trading Up 6.8% - Here's WhyKymera Therapeutics (NASDAQ:KYMR) Trading Up 6.8% - Here's WhyOctober 16, 2024 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Short Interest Down 7.2% in SeptemberKymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) was the recipient of a large decrease in short interest in the month of September. As of September 30th, there was short interest totalling 8,810,000 shares, a decrease of 7.2% from the September 15th total of 9,490,000 shares. Based on an average daily volume of 503,400 shares, the short-interest ratio is presently 17.5 days.October 16, 2024 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Moderate Buy" from AnalystsKymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the thirteen ratings firms that are covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating, eight have issued a buy rating andOctober 15, 2024 | marketbeat.comKymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 DegraderOctober 9, 2024 | globenewswire.comThe Manufacturers Life Insurance Company Raises Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)The Manufacturers Life Insurance Company grew its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 13.3% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 130,077 shares of the company's stOctober 8, 2024 | marketbeat.comHealthcare of Ontario Pension Plan Trust Fund Takes Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 64,000 shares of the company's stock, valued at appOctober 7, 2024 | marketbeat.comAmerican Century Companies Inc. Sells 36,820 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)American Century Companies Inc. decreased its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 77.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,847 shares of the company's stockOctober 4, 2024 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Stock Price Down 3.7%Kymera Therapeutics (NASDAQ:KYMR) Stock Price Down 3.7%October 2, 2024 | marketbeat.comSquarepoint Ops LLC Purchases 23,312 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)Squarepoint Ops LLC increased its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 27.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 108,563 shares of the company's stock after purchasingOctober 2, 2024 | marketbeat.comDriehaus Capital Management LLC Invests $6.67 Million in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Driehaus Capital Management LLC bought a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 223,413 shares of the companSeptember 30, 2024 | marketbeat.comMarshall Wace LLP Sells 196,364 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)Marshall Wace LLP trimmed its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 34.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 376,562 shares of the company's stock after selling 196,364September 29, 2024 | marketbeat.comOppenheimer Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)September 28, 2024 | markets.businessinsider.comKymera Therapeutics (NASDAQ:KYMR) PT Raised to $56.00Oppenheimer boosted their price objective on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the stock an "outperform" rating in a research note on Friday.September 27, 2024 | marketbeat.comProfund Advisors LLC Reduces Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Profund Advisors LLC trimmed its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 48.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,011 shares of the company's stock afSeptember 26, 2024 | marketbeat.comKymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV CongressSeptember 25, 2024 | globenewswire.comMassachusetts Financial Services Co. MA Has $12.12 Million Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)Massachusetts Financial Services Co. MA raised its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 2.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 405,870September 22, 2024 | marketbeat.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Director Sells $651,780.00 in StockSeptember 20, 2024 | insidertrades.comKymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of "Moderate Buy" from BrokeragesKymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) has earned an average rating of "Moderate Buy" from the thirteen analysts that are currently covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating, eight have given a buy raSeptember 20, 2024 | marketbeat.comKymera Therapeutics (NASDAQ:KYMR) Hits New 12-Month High at $50.69Kymera Therapeutics (NASDAQ:KYMR) Reaches New 52-Week High at $50.69September 19, 2024 | marketbeat.com Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run… All you have to do is follow this link here KYMR Media Mentions By Week KYMR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KYMR News Sentiment▼0.390.46▲Average Medical News Sentiment KYMR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KYMR Articles This Week▼45▲KYMR Articles Average Week Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BEAM News Today NRIX News Today REPL News Today EDIT News Today ALVR News Today ATRA News Today PCVX News Today CTLT News Today SRPT News Today RVMD News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KYMR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
